Primary outcomes Mortality Until day 14, death occurred in five patients (8.33%) in the antiviral preparation group, while in 36 patients (60%) of the control group, which means highly significant difference in mortality between medication and placebo groups.
← all excerpts
Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial.
1
—
—